A Phase 3 interventional study of Insulin Icodec and Semaglutide in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 39 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.
Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 13th largest by enrollment, is one of 3 that started in 2023, is one of 9 in phase 3, and was the 22nd registered.
10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Canada, Germany, Italy
Ages 18+
Xi'an International Medical Center Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 84 across the 27 interventional studies. Of the 25 that completed or were terminated, 12 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 27 have an industry lead sponsor. The 2 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
644 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 26 open now, 30 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 644 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 245th largest by enrollment of the 429 interventional ones that give a count, is one of 15 that started in 2023, is one of 187 in phase 3, and was the 582nd registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin icodec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07747402Xi'an International Medical Center HospitalInsulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 644 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study looks at how a new medicine insulin icodec helps in reducing blood sugar levels when given along with semaglutide in patients with type 2 diabetes. Participants will get the medicine insulin icodec once a week in the first part of the study (run-in period-26 weeks). Participants will only enter the second part of the study if the blood sugar levels have not reduced to normal. If blood sugar levels are normal after the first 26 weeks, participants will continue in a 5-week follow up period. In the second part of the study (intensification period-26 weeks), participants will get both insulin icodec and semaglutide once weekly after which they will continue in a 5-week follow up period. Participants will have to inject the study medicines once a week on the same day of the week in a skin fold in the thigh, upper arm or stomach. The study will last for about 13 months. Participants will get a blood glucose meter to check blood sugar levels. In addition, participants will be asked to enter blood sugar levels in the study phone. In addition, Participants will be asked to enter selected few blood sugar values (three times during the study) in a paper diary that will be provided to participants. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive insulin icodec once weekly for 26 weeks in run-in period to ensure the dose optimization. Thereafter, participants meeting intensification criteria will proceed to the 26-week treatment period to receive once weekly semaglutide subcutaneously starting from 0.25 milligrams (mg) and dose increased up to 1 mg along with 700 units per milliliter (U/mL) insulin icodec therapy. There are no maximum or minimum insulin doses.
Drug: Insulin Icodec · Drug: Semaglutide
Participants will receive subcutaneously insulin icodec once weekly for 52 weeks.
Participants will receive once weekly semaglutide subcutaneously starting from 0.25 mg and dose increased up to 1 mg for 26 weeks.
Change in Glycated Haemoglobin (HbA1c)
Change in HbA1c (percentage) from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.
Time frame: Baseline (Week 26), Week 52
Change in Mean 7-point Self-measured Plasma Glucose (SMPG) Profiles
Change in mean 7-point SMPG profiles from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.
Time frame: Baseline (Week 26), Week 52
Change in Mean Post-prandial Glucose Increment (Over All Meals)
Change in mean post-prandial glucose increment from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.
Time frame: Baseline (Week 26), Week 52
Change in Fasting Plasma Glucose (FPG)
Change in FPG from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.
Time frame: Baseline (Week 26), Week 52
Number of Severe Hypoglycaemic Episodes (Level 3)
Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).
Time frame: From baseline (week 26) to week 57
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than [<] 3.0 mmol/L [54 Milligrams Per Deciliter {mg/dL}], Confirmed by Blood Glucose [BG] Meter)
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).
Time frame: From baseline (week 26) to week 57
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L [54 mg/dL]), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).
Time frame: From baseline (week 26) to week 57
Change in Body Weight
Change in body weight from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).
Time frame: Baseline (Week 26), Week 52
Relative Change in Weekly Insulin Icodec Dose
Relative change in weekly insulin icodec dose from week 25 to week 52 is presented.
Time frame: From week 25 to week 52
The trial was conducted in 5 countries as follows: Poland, Serbia, Czechia, Malaysia and Thailand.
| Milestone | Insulin Icodec + Semaglutide |
|---|---|
| Started | 148 |
| Exposed | 148 |
| Safety analysis set (sas) | 148 |
| Completed | 94 |
| Not completed | 54 |
| Withdrew: Failing to meet intensification requirements | 51 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Death | 1 |
| Milestone | Insulin Icodec + Semaglutide |
|---|---|
| Started | 94 |
| Exposed | 94 |
| Full analysis set (fas) | 94 |
| Completed | 91 |
| Not completed | 3 |
| Withdrew: Failing to meet intensification requirements | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lost to follow-up | 1 |
Change in HbA1c (percentage) from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.
| Percentage (%) of HbA1c | Insulin Icodec + Semaglutide |
|---|---|
| Change in Glycated Haemoglobin (HbA1c) | -1.23 ± 0.86 |
Change in mean 7-point SMPG profiles from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.
| millimoles per liter (mmol/L) | Insulin Icodec + Semaglutide |
|---|---|
| Change in Mean 7-point Self-measured Plasma Glucose (SMPG) Profiles | -1.69 ± 2.42 |
Change in mean post-prandial glucose increment from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.
| mmol/L | Insulin Icodec + Semaglutide |
|---|---|
| Change in Mean Post-prandial Glucose Increment (Over All Meals) | -1.27 ± 2.17 |
Change in FPG from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.
| mmol/L | Insulin Icodec + Semaglutide |
|---|---|
| Change in Fasting Plasma Glucose (FPG) | -1.29 ± 2.24 |
Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).
| Episodes | Insulin Icodec + Semaglutide |
|---|---|
| Number of Severe Hypoglycaemic Episodes (Level 3) | 0 |
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).
| Episodes | Insulin Icodec + Semaglutide |
|---|---|
| Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than [<] 3.0 mmol/L [54 Milligrams Per Deciliter {mg/dL}], Confirmed by Blood Glucose [BG] Meter) | 13 |
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).
| Episodes | Insulin Icodec + Semaglutide |
|---|---|
| Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L [54 mg/dL]), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) | 13 |
Change in body weight from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).
| Kilograms (Kg) | Insulin Icodec + Semaglutide |
|---|---|
| Change in Body Weight | -3.85 ± 3.98 |
Relative change in weekly insulin icodec dose from week 25 to week 52 is presented.
| Insulin Units per Week | Insulin Icodec + Semaglutide |
|---|---|
| Relative Change in Weekly Insulin Icodec Dose | 0.76 (0.72 to 0.81) |
Collected over Week 0 to week 57. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Icodec: Run-in Period | 1/148 (0.7%) | 7/148 (4.7%) | 14/148 (9.5%) |
| Insulin Icodec + Semaglutide: Treatment Period | 0/94 (0%) | 3/94 (3.2%) | 50/94 (53.2%) |
| Event | Icodec: Run-in Period | Insulin Icodec + Semaglutide: Treatment Period |
|---|---|---|
| HydroceleCongenital, familial and genetic disorders | 0/148 | 1/94 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/148 | 1/94 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/148 | 1/94 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/148 | 1/94 |
| PhimosisCongenital, familial and genetic disorders | 1/148 | 0/94 |
| Angina PectorisCardiac disorders | 1/148 | 0/94 |
| GangreneInfections and infestations | 1/148 | 0/94 |
| Anticoagulation Drug Level IncreasedInvestigations | 1/148 | 0/94 |
| Metastases To LiverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/148 | 0/94 |
| Rectal CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/148 | 0/94 |
| Event | Icodec: Run-in Period | Insulin Icodec + Semaglutide: Treatment Period |
|---|---|---|
| NauseaGastrointestinal disorders | 0/148 | 18/94 |
| VomitingGastrointestinal disorders | 0/148 | 8/94 |
| Upper respiratory tract infectionInfections and infestations | 6/148 | 7/94 |
| Decreased appetiteMetabolism and nutrition disorders | 0/148 | 6/94 |
| DyspepsiaGastrointestinal disorders | 0/148 | 6/94 |
| Diabetic RetinopathyEye disorders | 8/148 | 0/94 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/148 | 5/94 |
Safety analysis set (SAS) included all participants who were exposed to investigational intervention (s).
| Age, Continuous(Years) | Insulin Icodec + Semaglutide |
|---|---|
| Mean | 60.11 ± 9.75 |
| Sex: Female, Male(Participants) | Insulin Icodec + Semaglutide |
|---|---|
| Female | 68 |
| Male | 80 |
| Ethnicity (NIH/OMB)(Participants) | Insulin Icodec + Semaglutide |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 148 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Insulin Icodec + Semaglutide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 40 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 108 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Sep 2023 to primary completion in Apr 2025, 18 months.
Results were first posted in Jun 2026, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin icodec · Semaglutide